These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7744521)

  • 1. Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis.
    Berta E; Confalonieri P; Simoncini O; Bernardi G; Busnach G; Mantegazza R; Cornelio F; Antozzi C
    Int J Artif Organs; 1994 Nov; 17(11):603-8. PubMed ID: 7744521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of IgG subclasses of anti-acetylcholine receptor antibodies in myasthenic plasma by immunoadsorption to protein A.
    Szpirt W; Somnier F; Nielsen FC; Rødgaard A
    Life Support Syst; 1985; 3 Suppl 1():351-5. PubMed ID: 3916613
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
    Pták J
    Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma exchange with selective immunoadsorption of anti-acetylcholine receptor antibodies.
    Somnier FE; Langvad E
    J Neuroimmunol; 1989 Apr; 22(2):123-7. PubMed ID: 2647782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
    Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
    Ohkubo A; Okado T; Sakurasawa T; Maeda T; Itagaki A; Yamamoto H; Miyamoto S; Seshima H; Kurashima N; Mori T; Iimori S; Sohara E; Rai T; Uchida S; Naito S
    Ther Apher Dial; 2019 Jun; 23(3):271-278. PubMed ID: 31025833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients.
    Benny WB; Sutton DM; Oger J; Bril V; McAteer MJ; Rock G
    Transfusion; 1999 Jul; 39(7):682-7. PubMed ID: 10413274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic apheresis in myasthenia gravis.
    Batocchi AP; Evoli A; Di Schino C; Tonali P
    Ther Apher; 2000 Aug; 4(4):275-9. PubMed ID: 10975473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.
    Takamori M; Maruta T
    Ther Apher; 2001 Oct; 5(5):340-50. PubMed ID: 11778918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoadsorption therapy for myasthenia gravis.
    Shibuya N; Sato T; Osame M; Takegami T; Doi S; Kawanami S
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):578-81. PubMed ID: 8201327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunopathology of myasthenia gravis.
    Lennon VA
    Hum Pathol; 1978 Sep; 9(5):541-51. PubMed ID: 309428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis.
    Sato T; Ishigaki Y; Komiya T; Tsuda H
    Ann N Y Acad Sci; 1988; 540():554-6. PubMed ID: 3061349
    [No Abstract]   [Full Text] [Related]  

  • 13. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunoadsorption--a new treatment of myasthenia gravis].
    Berning T; Krummenerl T; Glaser J; Paulus H; van Husen N
    Med Klin (Munich); 1988 Feb; 83(4):125-8. PubMed ID: 3285161
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety, stability, and effectiveness of immunoadsorption under membrane plasmapheresis treatment for myasthenia gravis.
    Hosokawa S; Oyamaguchi A
    ASAIO Trans; 1990; 36(3):M207-8. PubMed ID: 2252658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of myasthenia gravis by immunoadsorption of plasma.
    Grob D; Simpson D; Mitsumoto H; Hoch B; Mokhtarian F; Bender A; Greenberg M; Koo A; Nakayama S
    Neurology; 1995 Feb; 45(2):338-44. PubMed ID: 7854536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review.
    Bennani HN; Lagrange E; Noble J; Malvezzi P; Motte L; Chevallier E; Rostaing L; Jouve T
    J Clin Apher; 2021 Jun; 36(3):348-363. PubMed ID: 33349954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis.
    Takamori M; Ide Y
    Transfus Sci; 1996 Sep; 17(3):445-53. PubMed ID: 10163553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma treatment in diseases of the neuromuscular junction.
    Cornelio F; Antozzi C; Confalonieri P; Baggi F; Mantegazza R
    Ann N Y Acad Sci; 1998 May; 841():803-10. PubMed ID: 9668333
    [No Abstract]   [Full Text] [Related]  

  • 20. Selective removal of anti-acetylcholine receptor antibodies and IgG in vitro with an immunoadsorbent containing immobilized sulfathiazole.
    Yamamoto Y; Sameshima T; Akaike T
    Artif Organs; 1990 Oct; 14(5):334-41. PubMed ID: 2241600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.